沉默TREM1改善免疫抑制增强PD-1抑制剂抗肝癌作用及基于调控代谢影响TAM极化的中药活性分子筛选
摘要
肝癌因其恶性程度高严重影响患者生命健康,免疫治疗逐渐成为肝癌药物治疗的主要手段,免疫抑制性肿瘤微环境常导致肝癌免疫治疗疗效不佳,寻找改善免疫抑制的靶点和药物尤为重要.本研究通过生物信息学分析发现TREM1的表达与肝癌病理进展呈正相关,且高表达TREM1的患者显示了更差的临床预后.此外,TREM1主要表达于巨噬细胞内,并在肿瘤微环境中与巨噬细胞关系最为密切.在体外实验中,敲低TREM1可以抑制肿瘤相关巨噬细胞的免疫抑制表型,且通过小鼠皮下瘤模型证明敲低TREM1与PD-1抑制剂具有协同抗肿瘤作用.RNA测序发现TREM1对代谢相关途径具有调控作用,进一步通过文献分析及分子对接表明代谢相关中药活性成分可能通过靶向TREM1调控TAM代谢发挥抗肝癌作用.本研究有助于为中医药对肝癌的免疫调节提供新的理论依据.
Hepatocellular carcinoma(HCC),characterized by its high malignancy,poses a serious threat to patient survival and health.Immunotherapy has increasingly emerged as a key therapeutic strategy for HCC;however,the immunosuppressive tumor microenvironment(TME)frequently undermines its efficacy.Therefore,identifying molecular targets and therapeutic agents capable of alleviating this immunosuppression is of paramount importance.In this study,bioinformatics analyses revealed that triggering receptor expressed on myeloid cells-1(TREM1)expression correlated positively with HCC progression,and elevated TREM1 levels were associated with poorer clinical outcomes.Notably,TREM1 was predominantly expressed in macrophages and exhibited the strongest interaction with these cells within the TME.Functional in vitro assays demonstrated that silencing TREM1 attenuated the immunosuppressive phenotype of tumor-associated macrophages(TAMs).In a subcutaneous mouse tumor model,TREM1 knockdown synergized with PD-1 blockade to enhance anti-tumor efficacy.RNA sequencing further indicated that TREM1 modulated metabolism-related pathways.Complementary literature review and molecular docking analyses suggested that specific bioactive compounds derived from traditional Chinese medicine(TCM)might exert anti-HCC effects by targeting TREM1 and regulating TAM metabolism.Collectively,these findings provided a novel mechanistic framework for understanding the immunomodulatory potential of TCM in HCC therapy.
年,卷(期):
2026, 35(5)
分类号:
R96
机标分类号:
R730.2
R329.2
R979.1
在线出版日期:
2026年7月2日